News articles about Eli Lilly And Co (NYSE:LLY) have been trending neutral this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive press coverage by analyzing more than 6,000 blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Eli Lilly And Co earned a media sentiment score of 0.27 on their scale. InfoTrie also assigned news headlines about the company an news buzz score of 10 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock’s share price in the immediate future.
Here are some of the headlines that may have impacted Eli Lilly And Co’s score:
Several equities research analysts have recently weighed in on the stock. Cantor Fitzgerald set a $100.00 target price on shares of Eli Lilly And Co and gave the stock a “buy” rating in a research report on Tuesday, July 24th. Societe Generale set a $106.00 target price on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research report on Wednesday. ValuEngine downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday. Credit Suisse Group set a $84.00 target price on shares of Eli Lilly And Co and gave the stock a “hold” rating in a research report on Friday, July 13th. Finally, Jefferies Financial Group set a $100.00 target price on shares of Eli Lilly And Co and gave the stock a “buy” rating in a research report on Sunday, July 15th. Nine research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Eli Lilly And Co currently has an average rating of “Buy” and an average price target of $111.19.
Shares of NYSE LLY traded up $3.87 during midday trading on Wednesday, hitting $109.77. The company’s stock had a trading volume of 5,086,403 shares, compared to its average volume of 4,444,207. Eli Lilly And Co has a 1-year low of $73.69 and a 1-year high of $116.61. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.09 and a current ratio of 1.40. The firm has a market capitalization of $114.65 billion, a PE ratio of 25.65, a price-to-earnings-growth ratio of 1.73 and a beta of 0.29.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Tuesday, November 6th. The company reported $1.39 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.35 by $0.04. Eli Lilly And Co had a negative net margin of 0.60% and a positive return on equity of 39.84%. The business had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. During the same period in the previous year, the business posted $1.05 EPS. The company’s quarterly revenue was up 7.1% on a year-over-year basis. Equities analysts forecast that Eli Lilly And Co will post 5.47 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, December 10th. Stockholders of record on Thursday, November 15th will be issued a $0.5625 dividend. This represents a $2.25 annualized dividend and a dividend yield of 2.05%. The ex-dividend date of this dividend is Wednesday, November 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 52.57%.
In other news, major shareholder Eli & Co Lilly sold 4,531 shares of Eli Lilly And Co stock in a transaction dated Monday, August 13th. The shares were sold at an average price of $14.33, for a total value of $64,929.23. Following the completion of the transaction, the insider now directly owns 3,934,137 shares of the company’s stock, valued at approximately $56,376,183.21. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 174,696 shares of Eli Lilly And Co stock in a transaction dated Wednesday, October 17th. The shares were sold at an average price of $113.25, for a total transaction of $19,784,322.00. Following the completion of the transaction, the insider now directly owns 119,005,804 shares of the company’s stock, valued at $13,477,407,303. The disclosure for this sale can be found here. Insiders sold a total of 1,185,271 shares of company stock valued at $123,843,752 over the last ninety days. Company insiders own 0.11% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Eli Lilly And Co (LLY) Given Coverage Optimism Rating of 0.27” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/11/07/eli-lilly-and-co-lly-given-coverage-optimism-rating-of-0-27.html.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
See Also: How to Use the New Google Finance Tool
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.